| Literature DB >> 31174535 |
Jennifer Huberty1, Ryan Eckert2, Amylou Dueck3, Heidi Kosiorek3, Linda Larkey4, Krisstina Gowin5, Ruben Mesa2.
Abstract
BACKGROUND: Myeloproliferative neoplasm (MPN) patients suffer from significant symptoms, inflammation and reduced quality of life. Yoga improves these outcomes in other cancers, but this hasn't been demonstrated in MPNs. The purpose of this study was to: (1) explore the limited efficacy (does the program show promise of success) of a 12-week online yoga intervention among MPN patients on symptom burden and quality of life and (2) determine feasibility (practicality: to what extent a measure can be carried out) of remotely collecting inflammatory biomarkers.Entities:
Keywords: Cancer; Complementary; Mindfulness; Neoplasm; Physical activity
Mesh:
Substances:
Year: 2019 PMID: 31174535 PMCID: PMC6556039 DOI: 10.1186/s12906-019-2530-8
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Fig. 1A depiction of study participant enrollment into the study
Baseline Demographics & Patient-Reported Outcomes
| Yoga Group ( | Control Group ( | Total ( | ||
|---|---|---|---|---|
| N (%) | N (%) | N (%) | p | |
| Age, years (M ± SD) | 58.3 ± 9.3 | 55.0 ± 11.4 | 56.9 ± 10.3 | 0.28 |
| Body Mass Index (M ± SD) | 26.6 ± 5.4 | 26.2 ± 5.6 | 26.5 ± 5.4 | 0.81 |
| Gender | 0.71 | |||
| Male | 2 (7.4) | 1 (4.8) | 3 (6.3) | |
| Female | 25 (92.6) | 20 (95.2) | 45 (93.8) | |
| Race | 0.42 | |||
| Caucasian | 25 (92.6) | 20 (95.2) | 45 (93.8) | |
| Other | 2 (7.4) | 1 (4.8) | 3 (6.3) | |
| Diagnosis | 0.53 | |||
| Polycythemia Vera | 10 (37.0) | 5 (23.8) | 15 (31.3) | |
| Essential Thrombocythemia | 9 (33.3) | 10 (47.6) | 19 (39.6) | |
| Myelofibrosis | 8 (29.6) | 6 (28.6) | 14 (29.2) | |
| Time Since Diagnosis | 0.44 | |||
| < 1 year ago | 3 (11.1) | 4 (19.0) | 7 (14.6) | |
| 1–3 years ago | 4 (14.8) | 4 (19.0) | 8 (16.7) | |
| > 3 years ago | 20 (74.1) | 13 (61.9) | 33 (68.8) | |
| Presence of Enlarged Spleen | 0.45 | |||
| Yes | 8 (29.6) | 9 (42.9) | 17 (35.4) | |
| No | 17 (63.0) | 12 (57.1) | 29 (60.4) | |
| Missing | 2 (7.4) | 0 (0.0) | 2 (4.2) | |
| History of Anemia | 0.23 | |||
| Yes | 15 (55.6) | 8 (38.1) | 23 (47.9) | |
| No | 12 (44.4) | 13 (61.9) | 25 (52.1) | |
| Ruxolitinib/Other Janus Kinase-Inhibitor Treatment | 0.65 | |||
| Yes | 5 (18.5) | 5 (23.8) | 10 (20.8) | |
| No | 22 (81.5) | 16 (76.2) | 38 (79.2) | |
| Education | 0.3 | |||
| < High School | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| High school diploma | 2 (7.4) | 0 (0.0) | 2 (4.2) | |
| Some college | 1 (3.7) | 2 (9.5) | 3 (6.3) | |
| Associates/2-year degree | 3 (11.1) | 0 (0.0 | 3 (6.3) | |
| Bachelors degree | 10 (37.0) | 8 (38.1) | 18 (37.5) | |
| Graduate school or above | 11 (40.7) | 11 (52.4) | 22 (45.8) | |
| Marital status | 0.28 | |||
| Single | 2 (7.4) | 0 (0.0) | 2 (4.2) | |
| Partnered/in a relationship | 1 (3.7) | 2 (9.5) | 3 (6.3) | |
| Married | 22 (81.5) | 19 (90.5) | 41 (85.4) | |
| Separated | 2 (7.4) | 0 (0.0) | 2 (4.2) | |
| Divorced | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
Fig. 2A comparison between self-report and Clicky yoga participation minutes
Fig. 3A visual depiction of blood draw completion rates
Baseline and changes from baseline scores for Patient-Reported Outcomes by group
| Yoga Group ( | Control Group ( | |||
|---|---|---|---|---|
| Mean (SD) | Mean (SD) |
| ||
| NIH Patient Reported Outcomes Measurement Information System Outcomes | Anxiety | |||
| Baseline | 54.0 (7.8) | 50.2 (8.6) | – | |
| Change from baseline, wk. 7 | −2.1 (5.0) | −0.7 (5.4) | − 0.27 | |
| Change from baseline, wk. 12 | −3.1 (5.7) | −1.3 (7.1) | −0.30 | |
| Change from baseline, wk. 16 | −4.2 (5.0) | −2.0 (7.2) | − 0.37 | |
| Depression | ||||
| Baseline | 49.3 (7.9) | 45.2 (6.0) | – | |
| Change from baseline, wk. 7 | −3.7 (6.3) | 0.3 (5.4) | −0.64 | |
| Change from baseline, wk. 12 | −3.8 (5.4) | 1.6 (7.7) | − 0.78 | |
| Change from baseline, wk. 16 | −4.4 (7.0) | −0.6 (7.1) | −0.53 | |
| Interest Sexual Activity | ||||
| Baseline | 43.0 (6.8) | 43.8 (8.0) | – | |
| Change from baseline, wk. 7 | −0.6 (5.8) | − 0.2 (4.6) | − 0.08 | |
| Change from baseline, wk. 12 | 0.4 (4.9) | 2.4 (4.2) | −0.43 | |
| Change from baseline, wk. 16 | 0.7 (5.0) | −0.4 (6.9) | 0.20 | |
| Mental Health | ||||
| Baseline | 45.1 (5.1) | 41.1 (5.0) | – | |
| Change from baseline, wk. 7 | −5.0 (7.2) | − 5.3 (5.0) | 0.05 | |
| Change from baseline, wk. 12 | −5.1 (5.0) | −4.8 (6.5) | −0.05 | |
| Change from baseline, wk. 16 | −5.2 (4.2) | −4.8 (5.0) | −0.11 | |
| Orgasm | ||||
| Baseline | 2.9 (1.9) | 3.0 (1.6) | – | |
| Change from baseline, wk. 7 | 0.0 (1.6) | 0.6 (1.6) | −0.37 | |
| Change from baseline, wk. 12 | −0.2 (0.6) | 0.1 (2.0) | −0.16 | |
| Change from baseline, wk. 16 | −0.3 (0.8) | 0.2 (1.9) | −0.35 | |
| Pain Intensity | ||||
| Baseline | 45.1 (8.6) | 40.4 (9.0) | – | |
| Change from baseline, wk. 7 | −1.6 (5.8) | 0.6 (7.5) | −0.34 | |
| Change from baseline, wk. 12 | −2.4 (7.0) | 0.6 (6.6) | −0.43 | |
| Change from baseline, wk. 16 | −3.2 (7.3) | 0.8 (8.4) | −0.51 | |
| Physical Health | ||||
| Baseline | 39.8 (3.1) | 40.0 (4.4) | – | |
| Change from baseline, wk. 7 | −6.3 (6.2) | −7.2 (6.8) | 0.14 | |
| Change from baseline, wk. 12 | −6.6 (6.0) | −3.5 (5.7) | −0.52 | |
| Change from baseline, wk. 16 | −6.9 (7.3) | −6.9 (6.9) | 0.01 | |
| Satisfaction Sex Life | ||||
| Baseline | 49.1 (12.6) | 46.7 (12.8) | – | |
| Change from baseline, wk. 7 | −1.0 (10.4) | 2.4 (6.0) | −0.38 | |
| Change from baseline, wk. 12 | −0.9 (6.6) | 2.9 (12.6) | −0.41 | |
| Change from baseline, wk. 16 | −1.7 (8.2) | −0.3 (11.4) | −0.15 | |
| Vaginal Discomfort | ||||
| Baseline | 48.0 (5.9) | 48.0 (4.3) | – | |
| Change from baseline, wk. 7 | 0.7 (4.0) | −1.5 (3.8) | 0.55 | |
| Change from baseline, wk. 12 | 0.5 (4.1) | −1.5 (5.6) | 0.43 | |
| Change from baseline, wk. 16 | −0.8 (3.2) | −2.3 (1.7) | 0.51 | |
| Sleep | ||||
| Baseline | 50.1 (6.2) | 48.8 (6.7) | – | |
| Change from baseline, wk. 7 | −2.3 (5.8) | 0.2 (5.2) | −0.44 | |
| Change from baseline, wk. 12 | −2.5 (5.9) | 1.0 (4.7) | −0.61 | |
| Change from baseline, wk. 16 | −3.8 (7.6) | −2.1 (5.0) | −0.26 | |
| Quality of Life | ||||
| Baseline (1–5) | 3.1 (0.8) | 2.6 (0.9) | – | |
| Change from baseline, wk. 7 | −0.4 (0.6) | −0.4 (0.8) | 0.10 | |
| Change from baseline, wk. 12 | −0.1 (0.5) | −0.3 (0.9) | 0.34 | |
| Change from baseline, wk. 16 | −0.2 (0.5) | −0.3 (0.9) | 0.09 | |
| MPN Symptom Assessment Form Outcomes | Fatigue | |||
| Baseline (0–10) | 5.4 (2.3) | 4.5 (2.8) | – | |
| Change from baseline, wk. 7 | −0.7 (2.5) | −0.8 (3.1) | 0.02 | |
| Change from baseline, wk. 12 | −0.5 (2.2) | −0.6 (2.3) | 0.06 | |
| Change from baseline, wk. 16 | −0.7 (2.4) | 0.6 (2.0) | −0.56 | |
| Total Symptom Score | ||||
| Baseline (0–100) | 28.7 (15.6) | 21.9 (13.5) | – | |
| Change from baseline, wk. 7 | −1.4 (9.5) | −5.8 (11.2) | 0.44 | |
| Change from baseline, wk. 12 | −2.7 (8.5) | −4.1 (9.5) | 0.15 | |
| Change from baseline, wk. 16 | 4.4 (8.8) | 7.1 (8.7) | −0.31 | |
Note: lower scores represent an improvement for each measured outcome. NIH PROMIS outcomes are converted to standardized t-scores
acohen’s d was used for effect sizes